Grace Halsey

COVID-19 vaccines have been available for 6 months in the US under FDA EUAs. Many people stepped up ASAP; some remain in the wait and see camp. A new KFF survey parses motivation.

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.

Using data from wearable devices that track physiologic changes caused by viral illness, researchers observed prolonged deviation from baseline resting heart rate in study participants.

The most recent update to NIH COVID-19 Treatment Guidelines incorporates RCT data on use of antivirals, immunomodulators, and colchicine as treatment for SARS-CoV-2 infection.

Tezepelumab, a novel human monoclonal antibody that shows promise to reduce exacerbations across asthma phenotypes, was granted FDA Priority Review.

Empagliflozin, already indicated to improve outcomes in patients with HFrEF, reduced risk of a composite of CV death or hospitalization for HF in adults HFpEF, marking a potential therapeutic milestone.

The ACIP green lights mRNA vaccines with warning for myocarditis and pericarditis, says COVID-19 vaccine can be given on the same day as other common vaccines, advises COVID vaccine for all aged ≥12 yrs.

The Delta variant of SARS-CoV-2 now accounts for >20% of new US infections and WHO estimates is has spread to 96 countries. We summarize current data and perspective.

Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.

Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.

Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.

ADA 2021: The investigational exendin-4-based GLP-1 RA was associated with a 27% decrease in risk for a CV event and a 32% reduction in risk for CKD progression.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not GLP-1 receptor agonists were on board at study baseline.

The much anticipated results from the SURPASS 2 clinical trial demonstrated reductions in A1c and body weight with tirzepatide that were significant and superior to those with semaglutide.

ADA 2021. A prespecified subanalysis of FIDELIO-DKD found primary and secondary renal and CV endpoints consistent whether or not SGLT2 inhibitors were on board at study baseline.

STEP program investigator Robert F. Kushner, MD, reviews the "unprecedented" clinical trial results for semaglutide 2.4 mg and speaks specifically to primary care clinicians treating obesity.

Data released today at the American Diabetes Association 81st Scientific Sessions on a spike in new onset pediatric T2D at a single center during COVID-19 may signal much wider incidence.

Leading international diabetes researchers and clinicians will use the ADA's 81st annual Scientific Sessions as an ideal classroom to examine pandemic impact on diverse populations with diabetes.

Review of more than 300 clinical trials with products purported to facilitate weight loss found wide variability in risk of bias and data sufficiency suggesting caution among patients and physicians.

The CDC term "post-COVID conditions" includes the wide range of physical and emotional sequelae affecting many patients for ≥4 weeks post-infection.

Adults in their 30s and 40s who had high BMI in adolescence were at highest risk for type 2 diabetes and early MI, regardless of adult BMI, after 24 years of follow-up, a new study finds.

The American Diabetes Association 2021 Scientific Sessions run from June 25 to 29. This short slide show highlights 6 clinical trial updates that are a "must see" for primary care clinicians.

MOBILE study lead author Tom Martens, MD, talks about the inherent benefits of CGM for T2D patients on basal insulin treated in primary care and also the challenges to this vision of patient care.

MOBILE study lead author Thomas W. Martens, MD, discusses results of the study which was designed to capture CGM results in real-world primary care practice.

The CDC has intensified surveillance of the Delta variant of SARS-CoV-2 which now accounts for 10% of new US COVID-19 infections.

Patients with T2D see significant improvement in glycemic control using continuous glucose monitoring. MOBILE study lead author Thomas W. Martens, MD, highlights the evidence.

A new study found that patients with severe obesity who had even one discussion about bariatric surgery with a clinician were more likely to lose weight but that the discussions are infrequent.

A new study challenges traditional criteria for patient selection for metabolic surgery, demonstrating significant weight loss and disease remission for those with BMI of 30-35.

The vaccine is indicated for prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae serotypes.

Analysis of NHANES data shows significant downturns in control of the 3 risk factors in patients with diabetes, which could mean population-level increases in related illness.